AveXis (NASDAQ:AVXS) has been given a $147.00 price target by analysts at Mizuho in a note issued to investors on Wednesday. The brokerage presently has a “buy” rating on the stock. Mizuho’s target price would indicate a potential upside of 11.91% from the company’s previous close.
AVXS has been the subject of several other reports. Canaccord Genuity set a $110.00 target price on AveXis and gave the stock a “hold” rating in a report on Thursday, December 14th. Credit Suisse Group reiterated an “outperform” rating and issued a $139.00 target price (up from $134.00) on shares of AveXis in a report on Wednesday, February 28th. Royal Bank of Canada reiterated a “hold” rating and issued a $92.00 target price on shares of AveXis in a report on Tuesday, January 9th. BidaskClub cut AveXis from a “hold” rating to a “sell” rating in a report on Thursday, December 14th. Finally, UBS Group set a $143.00 target price on AveXis and gave the stock a “buy” rating in a report on Wednesday, February 28th. They noted that the move was a valuation call. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. AveXis presently has a consensus rating of “Buy” and a consensus target price of $123.90.
Shares of AveXis (NASDAQ:AVXS) traded down $3.05 during trading on Wednesday, reaching $131.36. The company’s stock had a trading volume of 436,879 shares, compared to its average volume of 551,290. The company has a market cap of $4,913.86, a P/E ratio of -18.22 and a beta of 2.02. AveXis has a 12 month low of $65.23 and a 12 month high of $138.46.
AveXis (NASDAQ:AVXS) last issued its earnings results on Tuesday, February 27th. The company reported ($2.55) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.64) by ($0.91). equities analysts forecast that AveXis will post -7.63 EPS for the current fiscal year.
In related news, VP Sukumar Nagendran sold 1,780 shares of the company’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $109.72, for a total transaction of $195,301.60. Following the completion of the sale, the vice president now directly owns 1,780 shares in the company, valued at approximately $195,301.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Brian K. Kaspar sold 15,000 shares of the company’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $109.75, for a total value of $1,646,250.00. Following the sale, the insider now owns 1,808,386 shares of the company’s stock, valued at $198,470,363.50. The disclosure for this sale can be found here. Insiders have sold a total of 65,560 shares of company stock valued at $7,793,030 over the last 90 days. 18.60% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of AveXis by 57.5% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,241 shares of the company’s stock worth $137,000 after purchasing an additional 453 shares during the last quarter. Amalgamated Bank lifted its stake in shares of AveXis by 19.6% during the 3rd quarter. Amalgamated Bank now owns 3,187 shares of the company’s stock worth $308,000 after purchasing an additional 523 shares during the last quarter. Emory University lifted its stake in shares of AveXis by 3.4% during the 4th quarter. Emory University now owns 18,474 shares of the company’s stock worth $2,045,000 after purchasing an additional 607 shares during the last quarter. Jennison Associates LLC increased its position in AveXis by 0.5% during the 4th quarter. Jennison Associates LLC now owns 185,094 shares of the company’s stock valued at $20,484,000 after buying an additional 883 shares in the last quarter. Finally, Swiss National Bank increased its position in AveXis by 2.8% during the 4th quarter. Swiss National Bank now owns 43,500 shares of the company’s stock valued at $4,814,000 after buying an additional 1,200 shares in the last quarter. Hedge funds and other institutional investors own 82.43% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This report was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/03/15/avexis-avxs-pt-set-at-147-00-by-mizuho.html.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.